To the Editor: In the editorial accompanying the article by Rajkumar and colleagues (Dec. 21 issue)¹ on the results of the ORBITA-2 trial involving the use of percutaneous coronary intervention (PCI) in patients with stable angina, White² begins with a flawed premise: “The primary aim of treating patients with stable angina is to decrease symptoms and improve quality of life.” That is not the primary aim of treating these patients. Relieving angina is important, but the real priority in the management of stable angina is the provision of appropriate medical therapy to reduce the risk of myocardial infarction and sudden . . .

致编辑：在 Rajkumar 及其同事发表的文章（12 月 21 日）¹的社论中，该文章涉及对稳定型心绞痛患者进行经皮冠状动脉介入治疗 (PCI) 的 ORBITA-2 试验结果，White ²开头写道：一个有缺陷的前提：“治疗稳定型心绞痛患者的主要目的是减少症状并提高生活质量。”这不是治疗这些患者的主要目的。缓解心绞痛很重要，但治疗稳定型心绞痛的真正首要任务是提供适当的药物治疗，以降低心肌梗塞和突发性心肌梗塞的风险。 。 。